|
Up-regulated
|
|---|
|
Age/Tumor status
|
Method
|
Probe Hits
|
Unique Genes
|
Overlap
|
|---|
|
2 months/Early in tumorigenesis
|
CAM
|
46
|
40
| |
| |
Partek (p ≤ 0.05)
|
19
|
18
|
11
|
| |
Partek (p ≤ 0.01)
|
7
|
7
|
4
|
|
12 months/Established tumors
|
CAM
|
296
|
260
| |
| |
Partek (p ≤ 0.05)
|
303
|
283
|
71
|
| |
Partek (p ≤ 0.01)
|
64
|
63
|
16
|
|
Down-regulated
|
|
Age/Tumor status
|
Method
|
Probe Hits
|
Unique Genes
|
Overlap
|
|
2 months/Early in tumorigenesis
|
CAM
|
86
|
73
| |
| |
Partek (p ≤ 0.05)
|
18
|
18
|
10
|
| |
Partek (p ≤ 0.01)
|
7
|
7
|
5
|
|
12 months/Established tumors
|
CAM
|
246
|
165
| |
| |
Partek (p ≤ 0.05)
|
470
|
432
|
46
|
| |
Partek (p ≤ 0.01)
|
92
|
89
|
13
|
- The number of differentially expressed probes hits and corresponding unique genes identified by a parametric (Partek) approach or nonparametric (CAM) approach are shown The overlap of genes identified by both approaches is also shown for p ≤ 0.05 or ≤ 0.01.
